InvestorsHub Logo
Followers 10
Posts 1244
Boards Moderated 0
Alias Born 10/12/2012

Re: None

Tuesday, 05/20/2014 11:16:50 AM

Tuesday, May 20, 2014 11:16:50 AM

Post# of 30990
Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis in Fierce Biotech Research, May 14, 2014

Excerpt:
"BLUE BELL, PA, USA I May 13, 2014 I Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College. Dr. Wang is a pioneer in the field of DNA therapies, having worked closely with Dr. David Weiner at the University of Pennsylvania. Dr. Wang was the primary author on some of the earliest DNA vaccine papers and patents. In consideration for these rights, Inovio will make clinical and regulatory milestone payments to the University.

These newly licensed technologies are based on patent-protected and published discoveries from Dr. Wang and his collaborator, who found a novel way to generate inducible regulatory T cells, or iTreg. iTreg cells are involved in shutting down immune responses after they have successfully eliminated invading organisms, and also in preventing autoimmunity or inflammatory diseases. In multiple published preclinical studies, this approach generated CD25-iTreg in an antigen-specific manner. These novel approaches could be used to develop therapies targeting major inflammatory diseases like multiple sclerosis and may be used to treat Alzheimer's disease.


Article at:
http://www.fiercebiotechresearch.com/press-releases/inovio-pharmaceuticals-acquires-early-stage-dna-therapies-treat-alzheimers#ixzz32GjxuHQg
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.